Patrick Daly

DocwireNews

Pulmonary function impairment was more frequent and inflammatory markers were elevated in pediatric patients with sickle cell disease (SCD) who experienced acute chest syndrome (ACS) versus those who did not experience ACS, according to an analysis of patient data from a previous randomized controlled trial, published in PLoS One.
The study, led by Aliva De, MD, of the Columbia University Irving Medical Center in New York, found a relationship between ACS and inflammation driven by interferon-inducible protein 10 (IP-10) and interleukin (IL)-6. “These findings suggest airway inflammation is present in children with SCD and ACS, which could be contributing to impaired pulmonary function,” Dr. De and colleagues wrote.
Researchers reviewed serum samples and pulmonary function test (PFT) data from 55 patients who had participated in a two-year clinical trial on high-dose and standard-dose vitamin D3 for the prevention of respiratory complications.
Compared with children with SCD without ACS, children with ACS had lower total lung capacity (TLC) at baseline and at year two, and had significant declines in forced expiratory volume in one second (FEV1; P=.015) and mid-maximal expiratory flow rate (P=0.39) over the study period. Children with ACS also had higher IL-5 and IL-13 serum cytokines at baseline and year two versus children without ACS.
Investigators noted that IP-10 and IL-6 were negatively correlated with PFT values. Based on multivariable regression models, age was significantly associated with FEV1 (P=.47) and FEV1 to forced vital capacity (FVC) ratios (P=.006). Additionally, males had lower FEV1/FVC ratios (P=.035) and higher TLC. Asthma was associated with FEV1 (P=.017) and FVC (P=.022), and history of ACS was significantly associated with TLC (P=.027).
Overall, “our present findings strengthen the association of ACS with lung function deficits and indicate that inflammatory mediators may be responsible,” Dr. De and colleagues wrote, concluding that, “with more insight into the underlying mechanisms of ACS in SCD leading to pulmonary injury, future therapeutic targets can be directed toward more specific disease mechanisms.”
Reference
De A, Williams S, Yao Y, et al. Acute chest syndrome, airway inflammation and lung function in sickle cell disease. PLoS One. 2023;18(3):e0283349. 2023. doi:10.1371/journal.pone.0283349

Pulmonary function impairment was more frequent and inflammatory markers were elevated in pediatric patients with sickle cell disease (SCD) who experienced acute chest syndrome (ACS) versus those who did not experience ACS, according to an analysis of patient data from a previous randomized controlled trial, published in PLoS One.The study, led by Aliva De, MD, of the Columbia University Irving Medical Center in New York, found a relationship between ACS and inflammation driven by interferon-inducible protein 10 (IP-10) and interleukin (IL)-6. “These findings suggest airway inflammation is present in children with SCD and ACS, which could be contributing to impaired pulmonary function,” Dr. De and colleagues wrote.Researchers reviewed serum samples and pulmonary function test (PFT) data from 55 patients who had participated in a two-year clinical trial on high-dose and standard-dose vitamin D3 for the prevention of respiratory complications.Compared with children with SCD without ACS, children with ACS had lower total lung capacity (TLC) at baseline and at year two, and had significant declines in forced expiratory volume in one second (FEV1; P=.015) and mid-maximal expiratory flow rate (P=0.39) over the study period. Children with ACS also had higher IL-5 and IL-13 serum cytokines at baseline and year two versus children without ACS.Investigators noted that IP-10 and IL-6 were negatively correlated with PFT values. Based on multivariable regression models, age was significantly associated with FEV1 (P=.47) and FEV1 to forced vital capacity (FVC) ratios (P=.006). Additionally, males had lower FEV1/FVC ratios (P=.035) and higher TLC. Asthma was associated with FEV1 (P=.017) and FVC (P=.022), and history of ACS was significantly associated with TLC (P=.027).Overall, “our present findings strengthen the association of ACS with lung function deficits and indicate that inflammatory mediators may be responsible,” Dr. De and colleagues wrote, concluding that, “with more insight into the underlying mechanisms of ACS in SCD leading to pulmonary injury, future therapeutic targets can be directed toward more specific disease mechanisms.”ReferenceDe A, Williams S, Yao Y, et al. Acute chest syndrome, airway inflammation and lung function in sickle cell disease. PLoS One. 2023;18(3):e0283349. 2023. doi:10.1371/journal.pone.0283349

Lauren Dembeck, PhD

FDA Authorizes First AI Platform for Breast Cancer Risk Prediction

Breast Cancer News

Izzah Nawaz

ACT-Based Parenting Program Improves Outcomes in Children With Both Asthma and ADHD

Neurodivergent

EGFR Inhibitors May Help Patients With Treatment-Resistant NF1-Mutant Melanoma

Melanoma

Latest News

How Does Acute Chest Syndrome in Sickle Cell Disease Impact Lung Function?

Sickle Cell Disease

Markers of pulmonary impairment and inflammation were elevated in children with sickle cell disease and acute chest syndrome compared with patients without acute chest syndrome.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe